HYBIO PHARMACEUTICAL CO., LTD.
|
Indications:
- As an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
- In patients undergoing percutaneous coronary intervention (PCI).
- For use in patients with, or at risk for, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
Mechanism of Action: Bivalirudin directly inhibits thrombin, preventing its action on fibrinogen and its activation of platelets. This leads to a reduction in clot formation and platelet aggregation, providing anticoagulant effects.
Pharmacokinetics:
- Absorption: Administered intravenously, it acts rapidly.
- Distribution: Limited distribution, primarily in the bloodstream.
- Metabolism: Cleaved by proteolytic enzymes.
- Excretion: Renal excretion.
Form: Bivalirudin API is typically found as a white to off-white lyophilized powder. |
Send Inquiry
|